Compare iShares MBS ETF (MBB) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MBS ETF vs Summit Therapeutics Inc — how do they compare? iShares MBS ETF trades at $89.75 (market cap $35.41B), while Summit Therapeutics Inc trades at $17.6 (market cap $13.71B). The key difference: iShares MBS ETF is far larger — about 2.6× Summit Therapeutics Inc's market cap, and Summit Therapeutics Inc is trading nearer its 52-week high, iShares MBS ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MBS ETF for 96 Days and Summit Therapeutics Inc for 16 Days on average.
| MBB | SMMT | |
|---|---|---|
Market Cap | $35.41B | $13.71B |
Volume | 5,388,525 | 6,173,057 |
Sector | Fixed Income | Health |
52-Week High | $96.91 | $26.38 |
52-Week Low | $89.09 | $12.43 |
Typical Hold Time | 96 Days | 16 Days |
Enterprise Value | — | $13.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MBB, the iShares MBS ETF, trades at $89.68, up 0.52% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The stock recently hit a new 52-week low of $91.02 on September 15, 2026, as short interest surged 98.3% in September, reflecting negative sentiment. Recent news highlights concerns over rising intermediate-term rates and inflation pressures impacting mortgage-backed securities.
The outlook remains cautious due to interest rate sensitivity and convexity risks in the mortgage market. While institutional buying by firms like Corient Private Wealth provides some support, the bearish technicals and macroeconomic headwinds suggest limited near-term upside. Key risks include further rate hikes and prepayment volatility in the MBS portfolio.
Summit Therapeutics (SMMT) trades at $17.44, down 2.84% on the day, with a bullish technical signal from moving averages and strong analyst support. The company shows no revenue but secured a major $2 billion strategic investment from AstraZeneca in September 2026 to advance its cancer drug ivonescimab, driving recent stock volatility and media attention. Financials reflect a pre-revenue biotech profile with significant losses, negative ROE of -192.5%, and cash flow supported by financing activities.
The outlook hinges on clinical success with ivonescimab, offering substantial upside to the $29.33 consensus price target if trials succeed, but high execution risk remains given the lack of revenue and deep losses. Investors face binary outcomes dependent on drug approval and commercialization timelines amid competitive oncology pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MBS ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index and TBAs that have economic characteristics that are substantially identical to the economic characteristics of the component securities of the index, and the fund will invest at least 90% of its assets in fixed income securities included in the underlying index that advisor believes will help the fund track the index.
Read more on MBB →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
